MS4A4A and Alzheimer disease: In addition, it was found that MS4A4A and TREM2 co-localize intracellularly, suggesting MS4A4A as a potential therapeutic target for AD [81]; Alector, Inc. is currently testing an antibody that mimics the protective effect of the MS4A4A variant.